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Abstract 
This paper proposes entitymetrics to measure the impact of knowledge units. Entitymetrics highlight the 
importance of entities embedded in scientific literature that for further knowledge discovery. In this paper, 
we use Metformin, a drug for diabetes, as an example to form an entity-entity citation network based on 
literature related to Metformin.  We then calculate the network features and compare the centrality ranks 
of biological entities with results from Comparative Toxicogenomics Database (CTD). The comparison 
demonstrates the usefulness of entitymetrics to detect most of the outstanding interactions manually 
curated in CTD. 
Introduction 
Currently, knowledge is being amassed rapidly; however, most of it is being encoded as strings in 
unstructured scientific literature. Extraction of this knowledge presently places a huge burden on already 
overloaded researchers, as they must manually dig out the embedded knowledge by reading tons of 
articles. This knowledge consists of many connected individual knowledge units encapsulated as entities 
in scientific papers. These entities could be authors, references, journals, and keywords that are 
commonly studied in scholarly evaluation, or they could be datasets, key methods, genes, drugs, and 
diseases that have not yet been widely explored in bibliometrics. Effective knowledge transfer depends on 
efficient knowledge accumulation. If these entities were decoded/annotated using a standard format (e.g. 
XML tags or RDF triples) and following shared semantics (e.g., domain ontologies, or controlled 
vocabularies), then connecting the entity dots would be as easy as flipping a switch. A knowledge graph 
could then be formed/accumulated automatically based on existing articles, and newly published articles, 
to lead potentially to successful knowledge discovery [1]. 
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Articles have been an essential entity used in bibliometric studies for decades. This entity can be 
aggregated to measure journal, author, institution, and country/state level impact or divided to understand 
keyword use. Entities are either evaluative entities or knowledge entities. Evaluative entities are used to 
evaluate scholarly impact, including papers, authors, journals, institutions, and/or countries. Scholars have 
mainly studied these entities for two purposes: 1) evaluation of scholarly impact, such as identifying top 
influential players in a specific field using an author citation analysis (e.g., [2]), ranking prestigious 
journals using journal citation networks (e.g., [3]), or exploring social, cognitive, and geographic 
relationships between institutions through paper citation networks (e.g., [4]) and 2) examination of  
scientific collaboration behavior, such as analyzing the structure of scientific collaboration networks (e.g., 
[5]-[6]), mining patterns of author orders in scientific publications (e.g., [7]), or characterizing 
international scientific co-authorship patterns (e.g., [8]). 
 
Knowledge entities act as carriers of knowledge units in scientific articles and include such entities as,  
keywords, topics, subject categories, datasets, key methods, key theories, and domain entities (e.g., 
biological entities: genes, drugs, and diseases). These knowledge entities are often to mine knowledge 
usage and transfer ultimately to facilitate knowledge discovery. Through co-word analysis, keywords 
have become a major knowledge unit used in current bibliometric analysis. However, they have 
limitations in detecting content interactions among scientific papers [9], portraying knowledge landscapes 
of specific domains [10] or science domains as a whole [11], and capturing existing schools of thoughts 
[12]. Recently, both subject categories and their upper level categories from the Web of Science (WOS) 
and/or Scopus have been used to analyze scientific trading between different domains [13]. 
 
The combination of evaluative entities and knowledge entities has been used to generate an overlay view 
of scholarly impact and knowledge usage to help interpret scholarly communication patterns through 
topical related explanation. Ding [14] combined evaluative entities (i.e., authors and papers) and 
knowledge entity (i.e. keywords) to explain whether productive authors tended to collaborate with and/or 
cite researchers with the same or different topical interests. Yan et al. [15] examined how research topics 
are mixed and matched in evolving research communities by using a hybrid approach to overlay keyword 
clusters and co-author networks. However, most bibliometric analyses use keywords as knowledge 
entities as they can be provided by WOS or Scopus and easily extracted from titles and abstracts.  
 
Few bibliometric analyses have extended this knowledge entity to the domain entity level (e.g., genes, 
drugs, and diseases). In the biomedical domain, research often revolves around important bio-entities, 
such as diseases (e.g., Alzheimer's disease, Obesity, depression), drugs (e.g., metformin (Diabetes), 
troglitazone (Diabetes), Amitriptyline (Depression)), and genes (e.g., BRCA1 (Breast Cancer), APP 
(Alzheimer's disease), and LEP (Obesity)) [78]. Yet, current bibliometric analyses have not used these 
bio-entities (e.g., genes, drugs, and diseases) as knowledge entities. Analysis of citation relationships 
between bio-entities targeting a specific disease, drug, or gene could be used to provide in-depth 
understanding of knowledge usage and transfer in specific cases, and ultimately lead to knowledge 
discovery. Extracting knowledge these units is easier in the well-established and semantically stable 
domains, such as medicine, mathematics, geology, and finance. In these domains, controlled vocabularies 
and tools for extracting knowledge units have been developed by the community and are in common 
practice. Conversely, in the social sciences and humanities, where the semantics of knowledge units 
cannot be explicitly modeled and are highly contextualized, it can be challenging to apply entitymetrics. 
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As an example, Hammarfelt [79] used page citation analysis (PCA) to trace how different parts of the 
frequently cited publication - Walter Benjamin's Illuminations 91968/2007 - had been cited to study the 
intellectual structures of the humanities.  
 
This paper proposes the new concept of entitymetrics (see Figure 1), which we define as using entities 
(i.e., evaluative entities or knowledge entities) in the measurement of impact, knowledge usage, and 
knowledge transfer to facilitate knowledge discovery. This extends bibliometrics by emphasizing the 
importance of entities, which are categorized as macro-level entities (e.g., author, journal, article), mesa-
level entities (e.g., keyword), and micro-level entities (e.g., dataset, method, domain entities). These 
entities can be analyzed from the temporal perspective to capture dynamic changes or from the spatial 
dimension to identify geographical differences. Entitymetrics focused on both knowledge usage and 
discovery and can be viewed as the next generation of citation analysis [76], as it aims to demonstrate 
how bibliometric approaches can be applied to knowledge entities and ultimately contribute to knowledge 
discovery.  
 
This paper uses Metformin, a drug for diabetes, as an example to illustrate the functionality and 
application of entitymetrics. Metformin was originally developed to treat Type II diabetes, but is now 
being considered in the treatment and prevention of cancer, obesity, depression, and aging [16]. Due to its 
significant drug repurposing function, Metformin has attracted great attention in diverse biomedical 
domains. This paper uses bio-entities as knowledge entities to analyze knowledge usage and transfer in 
Metformin related research. This paper is organized as follows: Section 2 outlines related work, Section 3 
details the methods we applied in the present paper, Section 4 provides and discusses the research results, 
and Section 5 concludes the research and identifies future work.   
Related Work 
Bibliometric research using evaluative entities  
The common evaluative entities in bibliometrics are papers, authors, and journals. These entities can be 
aggregated to research groups, universities/institutions, countries, or disciplines. Van Raan [20] applied 
paper and author citation analysis to 147 university chemistry research groups in the Netherlands. He 
compared those with peer review judgments and found the results were correlated. Boyack et al. [11] 
mapped the structure of science and social science based on the journal citation networks and journal co-
citation networks of 7,121 journals. H-index was proposed to combine the number of publications and 
number of citations to measure individual scientific achievement [21]. Co-author networks have been 
aggregated to the state and country levels to identify common patterns based on productivity and 
influence of author orders [7]. PageRank, and its variants, has been used to evaluate scientific impact, 
such as AuthorRank [22], Y-factor [3], CiteRank [23], FutureRank [24], Eigenfactor [25], and SCImago 
Journal Rank [26]. 
 
Bibliometric research using knowledge entities 
Pettigrew and McKechnie [27] traced the usage of theories in information science (IS) based on 1,160 
articles published in six information science journals. They analyzed both how authors applied IS theories 
in their published work and how those theories were used outside the field. They developed a code 
structure and manually coded each article. Through their analysis of these knowledge entities (e.g., IS 
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theories), they were able to identify over 100 distinct theories born in IS and conclude that IS theory was 
not well cited outside the field. Yan et al. [13] used 221 Web of Science subject categories as knowledge 
entities to study knowledge transfer in the sciences and social sciences based on the journal citation 
networks. They found that the social science fields were becoming more visible by exporting more 
knowledge in scientific trading. Small [77] used the combined method of quantitative (clustering) and 
qualitative approaches (content analysis) to detect the interdisciplinary linkage between document 
clustering and journal subject categories.  
 
Keyword is another important knowledge entity.  Co-word analysis was first implemented in a system 
called LEXIMAPPE [28]. The co-word approach extracts keywords from articles and forms a co-
occurrence matrix of these keywords. Callon, Courtial, and Laville [9] used keywords as knowledge 
entities to apply co-word analysis in the polymer science field. They identified the evolution of this field 
in different subject areas and demonstrated the research trajectories in a research network. Kostoff et al. 
[29] implemented another system called Database Tomography (DT), which extracted phrases and 
performed co-word analysis to detect relationships among themes and sub-themes. They demonstrated 
that co-word analysis could be used empirically to explain the emergence and diffusion of innovations 
[30]. However, the clustering method in the above co-word analyses is similar to the single linkage cluster 
algorithm, which is now considered unreliable [30]. Tijssen and Van Raan [31] showed that 
LEXIMAPPE could be replaced using multi-dimensional scaling (MDS). Leysdesdorff [32] pointed out 
several issues with LEXIMAPPE and proposed the use of factor analysis and other clustering techniques 
to conduct co-word analysis.  
 
Combination of evaluative entities and knowledge entities 
The combination of evaluative entities and knowledge entities can bring finer granularity to the ranking of 
evaluative entities by considering their contribution to concrete knowledge entities [33]. Ding [34] 
combined a knowledge entity (i.e.,topics) with an evaluative entity (i.e., author) to detect high impact 
authors in certain topics using topic-based PageRank. The Author-Conference-Topic (ACT) model, an 
extended Latent Dirichlet Allocation (LDA) model, has been used to extract topics and calculate topic 
distribution of individual authors and conferences [35]. Ding [14] analyzed scientific collaboration and 
citation networks by considering different topics as knowledge entities to determine whether productive 
authors tend to collaborate with, or cite, researchers with the same or different research topics and 
whether highly cited authors tend to collaborate with each other.  
 
Using entitymetrics to discover knowledge 
Swanson's work about undiscovered public knowledge has achieved a wide impact on association 
discovery and demonstrated that new knowledge can be discovered from sets of disjointed scientific 
articles [36]-[38]. Swanson [39] pointed out that bibliometrics can be a valuable tool for knowledge 
discovery given that it analyzes the citing and cited relationships of articles. Swanson further suggested 
that his method could be extended to many other disconnected literature sets to enable cross-disciplinary 
innovation [40]. Arrowsmith (http://arrowsmith.psych.uic.edu/arrowsmith_uic/index.html) was thus 
developed to enable semi-automatic knowledge discovery [41]. The basic assumption of Swanson's 
method is that knowledge developed in one field maybe unknown in another field. There are three ways 
to ensure the mutual exclusion for two literature sets [41]-[42]: 1) by excluding common papers which 
appear in both sets (they called A set and C set), 2) and even stricter, by excluding papers from both sets 
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which cite the same papers, and 3) the strictest, by making sure that papers from both sets have not been 
co-cited together before. There are several problems with Swanson's method. First, it is not easy to 
identify A and C directly without domain specific knowledge. For example, the popular example for 
Swanson's method uses Raynaud's Disease (A) and eicosapentaenoic acid (C), or magnesium deficiency 
(A) and migraine (C), which took years to identify hypotheses to test the connections between these 
specific diseases and drugs. Second, it is difficult to identify important terms connecting A and C sets 
(called B-terms) as there could be thousands of B-terms that link both sets. The rank of B-terms based on 
frequency, calculated from a Poisson distribution, is far from sufficient to identify potential breakthroughs. 
Usually the top-ranked B-terms, based on frequency, are known knowledge, while the low-ranked B-
terms are overwhelming in number and noisy. Gordon and colleagues improved the Swanson system by 
applying a statistical method to rank B-terms [43]-[44]. Weeber et al. [45] improved Swanson's model by 
converting terms to knowledge entities using the biomedical Unified Medical Language System (UMLS) 
concepts as units of analysis. Weeber's system has successfully simulated Swanson's discoveries of 
connecting Raynaud's disease with fish oil and migraine with magnesium deficiency thereby 
demonstrating the main advantage of using UMLS concepts over keywords. In doing so, they extended 
literature-based discovery to data-based discovery by involving databases, such as annotated genetic 
databases. Stegmann and Grohmann [46] applied Swanson's method to generate hypothesis for Raynaud's 
Disease that demonstrated co-word clustering as a powerful method for literature-based hypothesis 
generation and knowledge discovery. Bekhuis [47] summarized all developments and applications based 
on the early work of Swanson and claimed that Swanson's vision of the hidden value in the literature of 
science in biomedical digital databases is remarkably innovative for information scientists, biologists, and 
physicians.  
Methodology 
Metformin 
Metformin (N",N"-dimethylbiguanide) is often referred to as a magic drug. Originally, the drug was 
developed to treat Type II diabetes, however now, it is also being considered to treat and prevent cancer, 
obesity, depression, and aging [16]. Endocrinologists, cardiologists, oncologists, and aging specialists 
have generated waves of interest by attempting to use anti-diabetic biguanides to control body weight and 
tumor growth [48]. Metformin is the only anti-diabetic drug, which can prevent the cardiovascular 
complications of diabetes and remains as one, of the only two, oral anti-diabetics on the World Health 
Organization Model List of Essential Medicines [49]. Obesity and cancer have interrelationships with 
aging [50]. Metformin is able moderately to reduce body weight for obese diabetics because it can reduce 
insulin resistance and hyperinsulinemia [51]. A recent study found that children and adolescents are more 
responsive to metformin-induced weight loss compared to adults [52].  
 
Dataset 
PubMed and PubMed Central (PMC) are used to generate a biological entity citation network for 
Metformin related articles.  PubMed Central is the U.S. National Institutes of Health (NIH) digital archive 
of full-text biomedical and life sciences journal literature.  Our collection from PMC contains 353,592 
articles from 3,068 journals and our dataset from PubMed contains 20,494,848 papers published between 
the years 1966 and 2011. The dataset was used to extract citation relationships between papers with the 
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criteria that both citing papers and cited papers have PubMed IDs (PMID) so that bio-entities can be 
connected via citation. 
 
Biological Entity Extraction 
To identify entities in all PubMed articles, we employed a dictionary-based named entity recognition 
method with exact match. The dictionary, taken from Wang et al. [53], includes three parts: genes, 
diseases, and drugs. The dictionary is built from a Drug dictionary (DrugBank (http://www.drugbank.ca/)), 
a Target dictionary (HUGO (http://www.genenames.org/)), and a Disease dictionary (MESH disease from 
CTD (http://ctdbase.org/)). A small chunk of the dictionary is shown in Figure 2.  In the example entry 
(ACTA1-->GENE__P68133”, “actin, alpha 1, skeletal muscle-->GENE__P68133), ACTA1 is the name 
of the gene and P68133 is its MeshID. The example shows that, besides searching for “ACTA1” in the 
document, all the other synonyms or aliases (actin, alpha 1, and skeletal muscle) are also searched. The 
extraction was conducted on the title and abstract of each publication using the LingPipe library from the 
Alias–i project, which contains a package called Exact Dictionary-Based Chunking. After finishing the 
extraction, all the results were stored in a relational database to facilitate further processing.  
 
Entity Citation Network 
In the next step, we built a bio-entity citation network based on the concept that if paper A cites paper B, 
then an entity in paper A will be considered to cite an entity in paper B. Entities in the citing paper are 
paired with entities in all the cited papers (see Figure 3). A hash table is used to store the entity citation 
associations and their occurance frequency.  
 
Figure 4 illustrates the process used to create the entity citation network which includes three components: 
ArticleFilter, EntityFetcher, and GraphCreator. The ArticleFilter component extracts a set of referenences 
from the reference section of papers related to a target object (e.g., a diseasese, a concept, and a method), 
which are showed in squared parenthesis. Subsequently, the EntityFetcher component retrieves entities 
for this set of references. Finally, the GraphCreator component generates a hash table of entity citation 
relationships and counts the number of times each relationship occurs. In the final graph, vertices 
represent entities and edges represent citation relationships with number of citations as weights. In this 
paper, the ArticleFilter is applied to get the list of references from the PubMed papers related to 
Metformin, then the EntityFetcher collected extracted entities from this list of references, finally the 
GraphCreator generated a entity citation graph based on the entities retrieved from the EntityFetcher and 
citation relationships captured by the ArticleFilter. 
 
Metformin-related Entity Citation Network 
In order to guarantee the coverage of Metformin related articles, search terms were extended from only 
Metformin to include brand name and synonyms, as well as, related diseases and genes extracted from the 
CTD and DrugBank (see Table 1).  
 
The following search terms were used to search the downloaded PubMed Central dataset from NIH: 
("metformin"[ti] OR "metformin"[ab] OR "alstrom syndrome"[ti] OR "alstrom syndrome"[ab] OR 
"amyloidosis"[ti] OR "amyloidosis"[ab] OR "atrophy"[ti] OR "atrophy"[ab] OR "diabetes 
complications"[ti] OR "diabetes complications"[ab] OR "diabetes mellitus"[ti] OR "diabetes mellitus"[ab] 
OR "diabetes mellitus (experimental)"[ab] OR "diabetes mellitus (type 2)"[ti] OR "diabetes mellitus (type 
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2)"[ab] OR "diabetic angiopathies"[ab] OR "diabetic nephropathies"[ab] OR "hyperandrogenism"[ti] OR 
"hyperandrogenism"[ab] OR "hyperglycemia"[ti] OR "hyperglycemia"[ab] OR "hyperinsulinism"[ti] OR 
"hyperinsulinism"[ab] OR "hypertension"[ti] OR "hypertension"[ab] OR "insulin resistance"[ti] OR 
"insulin resistance"[ab] OR "myocardial infarction"[ti] OR "myocardial infarction"[ab] OR "obesity"[ti] 
OR "obesity"[ab] OR "polycystic ovary syndrome"[ti] OR "polycystic ovary syndrome"[ab] OR 
"albuminuria"[ti] OR "albuminuria"[ab]) AND ("1965/01/01"[PubDate] : "2011/12/31"[PubDate]). 
Finally, of the 4,770 articles retrieved from PubMed Central (the citing article set), only those references 
with PubMed IDs were kept (the cited article set), which resulted in 134,844 references. The references 
without PubMed IDs were not included, as bio-entities could not be extracted from these references. From 
the titles and abstracts of 4,770 full text articles, 1,969 bio-entities (i.e., 880 genes, 376 drugs, and 713 
diseases) were extracted. Table 2 shows the top 20 ranked bio-entities. 
  
In the cited article set (e.g., 134,844 references), 6,978 entities were extracted including 3,914 genes, 
1,296 drugs, and 1,768 diseases. Table 3 shows the top 20 ranked bio-entities, which are highly cited. 
 
Network Analysis Approaches 
Network analysis approaches consist of three levels: macro-level statistics (global graph metrics), meso-
level structures (cluster characters), and micro-level indicators (individual node properties). The macro-
level analyses includes component, bi-component, k-core, shortest distance, and degree distribution; the 
meso-level analyses mainly includes clustering coefficient, as in the current study, but may also include 
techniques such as, hierarchical clustering and modularity-based clustering; and the micro-level analyses 
refer to different centrality measures. For formal definitions of these approaches, readers can refer to 
Freeman [54]-[56] and Nooy, Mrvar, and Batagelj [57].  
 
Macro-level features 
Component analysis: In network analysis, connected graphs are called components. Component analysis 
can be used to learn about the macro-level structure of a network. Some network analysis methods (e.g., 
shortest distance) can only be used in connected networks, and thus, are only applied to the largest 
component. 
Bi-component analysis: In a bi-component graph, no node can control the information flow between two 
other nodes completely because there is always an alternative path that information may follow [57]. In a 
bi-component graph, each node receives information from at least two nodes. In these bi-components 
graphs, nodes share similar information and are identical to each other [58].  
K-core analysis: The k-core of a network is a sub-structure in which each node has ties to at least k other 
nodes [59]. Nodes in the core are tightly linked, thus ties in each k-core are strong ties [60]. Information 
transfer within a k-core maybe redundant, as one vertex can receive the same information more than once 
from other nodes in the same k-core.  
Distance analysis: A geodesic is the shortest path between two nodes. Many networks show that most 
individuals are at very few "degrees of distance" from one another [61]. The mean shortest distance 
between node pairs in a network can be expressed as: 
L = 1
NN+ 1	

d

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where	d is the geodesic distance from node i to node j; and N is the total number of nodes in the 
connected component.  
Degree distribution: The degree of a node is the number of other nodes connected to it. Nodes with 
higher degrees act as hubs in the network and are crucial to the robustness of the network, as well as, the 
flow of information. Degree distribution measures the character of a network: a few nodes have many 
links and a majority have a smaller numbers of links. Albert and Barabási [62] discovered that degree 
distribution in many real-world networks follows the power-law distribution: 	~ where k is the 
node degree and  is a constant. 
Meso-level features 
Networks contain local communities/clusters in which many nodes are “locally” connected with one 
another [5] [63]. Clustering coefficient is an effective meso-level indicator to estimate the locally 
clustering feature: 
 = 3 ×  !"#$!%&'( )"$ℎ '!&+ℎ !"#," ,$ -$!%+( )"#. !$%, ) 
This definition corresponds to the concept of the “fraction of transitive triples” used in sociology [64].  
Micro-level features 
Degree centrality: Degree centrality for a node is the number of links that a node has with others, which 
can be expressed as follows: 
)()( iiD ndnC =  
where )( ind is the degree of in . 
Closeness centrality: Unlike degree centrality, the closeness centrality of a node focuses on its 
extensibility of influence over the entire network and is expressed as: 
∑
=
=
N
i ji
i
nnd
n
1
c ),(
1)(C
 
where )(Cc in  is the closeness centrality, and  ),( ji nnd  is the distance between two nodes in the network. 
Betweenness centrality: Betweenness centrality is based on the number of shortest paths passing through 
a node. Nodes with a high betweenness serve as bridges that connect different sub-groups.  Betweenness 
is expressed as:  
jk
kj
i
iB g
n
nC
∑
<
=
)(
)(
 
where jkg  is the geodesic distance between the nodes of j and k. 
 
Evaluation 
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For evaluation, we use the CTD (Comparative Toxicogenomics Database) which contains 384,141 
chemical synonyms, 679,701 gene synonyms, and 68,211 disease synonyms. The CTD provides us with a 
set of 336,693 interactions between diseases and drugs. To measure the significance of Metformin in 
disease, we utilize the inference score, provided in the CTD, to measure the strength of the association 
between diseases and Metformin or its descendants. Each association is curated as either 
marker/mechanism or therapeutic, which is used for calculating the inference score. The inference score, 
proposed by King et al. [66], is used to represent the similarity of chemical–gene–disease networks in the 
CTD by comparing a scale-free random network with a similar topology. The higher the inference score, 
the more likely the inference network will show distinct linkage. 
 
Result and Discussion 
In total, the entity-entity citation network based on Metformin information contains 7,055 entities and 
264,345 links, among which 1,561 are loops (i.e. self-citations). 
Macro-level features 
All of the 7,055 entities belong to exactly one component and bi-component. This means that the network 
is well connected, as at least two distinct semi-paths connect every pair of entities. The density of a 
network shows the degree of connections between any given two pairs in this network. If it is applied to 
data with values, density shows the average strength of the ties across all possible ties. The density of the 
Metformin network is 0.005311, which means that 0.5311% of all possible connections are presented in 
the current network. According to the K-core analysis, the biggest k-core (188-core) consist of 238 
entities, which means that each entity in this sub-network has a connection with at least 188 others. The 
mean geodesic distance is 2.10. This means the average of shortest path between any two nodes is about 
two nodes long (not including the two given nodes). Therefore, information can be transferred efficiently 
through this network. The diameter (e.g., the largest geodesic distance between nodes pairs in the network) 
is four; between GENE otc and GENE ube2v1.This indicates that there is a close relation among all the 
entities, as every pair of entities could be reached by one another within three steps. Figure 5 shows the 
longest path (e.g., the diameter of the network) from Gene otc to Gene ube2v1. 
 
As the entity-entity citation network is a direct network, histograms can be used to show in-degree and 
out-degree distributions (Figure 6). A power law distribution was found in both the in-degree and out-
degree distributions. This means that a low portion of the nodes have a high in-degree/out degree links, 
while a majority of the nodes have very few in-degree/out-degree links. The results confirm Albert’s [65] 
study that most cellular interaction networks are scale-free. 
  
Meso-level features 
The clustering coefficient of the network was 0.684687, which indicates that entities in the Metformin 
network have a high tendency to cluster together. In Newman’s [63] review article, the author highlighted 
the properties of a few biological networks, including metabolic networks, protein interactions, marine 
food web, freshwater food web, and neutral network. The networks all have smaller average shortest 
paths (ranging from 1.9 to 6.8) and clustering coefficients (ranging from 0.09 to 0.20). The current 
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network also exhibits these small-world properties including, a small average shortest path (2.1) and a 
large clustering coefficient (0.68). 
Micro-level features 
The degree (in-degree and out-degree) centrality, closeness centrality, and betweenness centrality of this 
network were calculated. Entities with high centrality are listed in Tables 4-7 which contain the top 20 
ranks for each of three different kinds of entities (e.g., disease, drug, and gene) and for all the entities 
combined. 
 
There are 697 diseases ranked for Metformin in the CTD. In terms of in-degree centrality, we found 16 
matches including the four common terms: disease, syndrome, death, and body weight. The following 
three diseases ranked in top 10: Diabetes mellitus (1st), Obesity (7th), and Insulin resistance (9th). The six 
diseases ranked between 11th and 100th: Atherosclerosis (20th), Hypertension (21st), Myocardial infarction 
(28th), Inflammation (37th), Heart Failure (40th), and Stroke (74th).  The following seven diseases ranked 
low: Necrosis (102nd), Ischemia (120th), Coronary artery disease (174th), Infection (265th), Erythema 
(306th), Hyperglycemia (337th), and Hypertrophy (439th). 
Since the CTD curates specific drug-gene interactions in vertebrates and invertebrates from the published 
literature, we utilize this information to understand the importance of the genes identified in terms of in-
degree centrality. Among the 20 genes we identified, the following five matched with the CTD entries: 
TNF, LEP, JUN, CAT, and Glucagon. The most salient gene that interacts with Metformin is TNF. We 
found ten interactions between Metformin and TNF (ranked 3rd in the CTD). Studies have shown 
Metformin increases expression of the TNS protein, leading to improved hepatic steatosis, when co-
treated with rosiglitazone [67] and that Metformin reduces Streptozocin which thus results in an increased 
expression of TNF mRNA[68]-[69]. Regarding the interaction between Metformin and LEP, we found 
only one interaction consistent with reports that Metformin results in an increased expression of the LEP 
gene [70]. Between Metformin and JUN, we found only one interaction that Metformin inhibits 
Tetradecanoylphorbol Acetate, which affects the localization of JUN gene [71]. Between Metformin and 
CAT gene, we found three interactions stating that Metformin inhibits Streptozocin thus resulting in 
decreased expression of CAT mRNA [68]. Between Metformin and Glucagon, there are four interactions 
indicating that Metformin results in increased expression of IL1RN mRNS when co-treated with 
Glucagon [72]. 
 
Since the CTD does not provide information about the interaction between Metformin and other drugs, 
we consulted with a well-known drug interaction checker (http://www.drugs.com/drug-interactions). A 
drug interaction means that another drug affects the activity of the drug when both are administered 
together. This interaction can be either synergistic or antagonistic; and could sometimes produce effects 
not achieved by either drug individually. On the drug interaction checker website, we found 14 drugs to 
have a major interaction with Metformin and 589 drugs to have a moderate interaction with Metformin. 
Among the top 20 drugs identified in terms of in-degree centrality, the following four were identified as 
having a moderate interaction with Metformin according to the drug interaction checker: Dopamine, 
Dexamethasone, Ethanol, and Epinephrine. Dopamine is a monoamine neurotransmitter and hormone that 
plays a significant role in the body of animals. Dexamethasone is a steroid drug that acts as an anti-
inflammatory. Ethanol is a psychoactive drug that leads to a state of alcohol intoxication when consumed. 
Epinephrine is a hormone that carries out many crucial functions in the body such as regulating heart rate, 
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blood vessel, etc. Both Dopamine and Epinephrine have a synergistic relationship with Metformin by 
reducing its effects in lowering the blood sugar, whereas Dexamethasone has an antagonistic relationship 
with Metformin by causing a condition called lactic acidosis.  
 
Using out-degree centrality, we found 16 matched entries for disease. Compared to in-degree centrality, 
14 diseases are identical between in-degree and out-degree. Ischemia and coronary artery disease are not 
ranked in the top 20 for out-degree centrality. Three disease interactions, fibrosis, atrophy, and 
cardiovascular diseases, are newly ranked in top 20 for out-degree centrality. In the CTD, fibrosis ranked 
54th, cardiovascular disease ranked 112th, and Atrophy ranked 215th.     
 
For the interaction between Metformin and genes, out-degree centrality identifies five matched genes with 
the CTD: LEP, TNF, MMP9, JUN, and CRP. LEP and TNF are both explained above. We found four 
interactions between Metformin and MMP9 in the CTD. A study has shown that Metformin inhibits 
Tetradecanoylphorbol Acetate and results in increased activity of MMP9 gene [71]. We found that there 
are three interactions between Metformin and CRP consistent with reports that Metformin results in 
decreased expression of the CRP gene [73]-[74]. 
 
In the interaction between Metformin and other drugs, we found two matches with the drug interaction 
checker, Dopamine and Ethanol. Both are identified by in-degree centrality and are explained earlier.  
 
Using closeness centrality, we found 13 matches with no new interactions between Metformin and 
diseases identified. Among the 13 matches, the following three are in top 10: Diabetes mellitus (1st), 
Obesity (7th), and Insulin resistance (9th). Five diseases ranked between 11th and 100th including: 
Hypertension (21st), Myocardial infarction (28th), Inflammation (37th), Heart Failure (40th), and Stroke 
(74th).  The following six diseases ranked low: Necrosis (102nd), Atrophy (215th), Infection (265th), 
Erythema (306th), Hyperglycemia (337th), and Hypertrophy (439th). With respect to the interaction 
between Metformin and other drugs and the interaction between Metformin and genes, the closeness 
centrality identified four interactions: TNF, LEP, Glucagon, and JUN. There are no new interactions in 
top 20 genes found by closeness centrality. 
 
Using the betweenness centrality, we found 17 Metformin and disease interactions. The following three 
diseases ranked in the top 10: Diabetes mellitus (1st), Obesity (7th), and Insulin resistance (9th). Seven 
diseases ranked between 11th and 100th including: Atherosclerosis (20th), Hypertension (21st), Myocardial 
infarction (28th), Inflammation (37th), Heart Failure (40th), Fibrosis (54th), and Stroke (74th).  The 
following seven diseases ranked low: Necrosis (102nd), Ischemia (120th), Atrophy (215th), Infection (265th), 
Erythema (306th), Hyperglycemia (337th), and Hypertrophy (439th). 
 
The following four genes interaction with Metformin are identified by betweenness centrality: TNF, LEP, 
MMP9, and Glucagon (all genes are explained earlier). For Metformin and drug interaction, the following 
four drugs are identified: Dopamine, Dexamethasone, Testosterone, and Epinephrine. The newly 
identified drug by betweenness centrality, Testosterone, is a steroid hormone that plays an imperative role 
in developing male reproductive tissues such as the testis and prostate. Like the other three drugs, 
testosterone reduces the effects of Metformin by lowering the blood sugar.  
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Conclusion 
This paper proposes entitymetrics to measure the impact of knowledge units at different levels. It 
highlights the importance of entities embedded in scientific literature for further knowledge discovery. 
Compared with the related work, entitymetrics advances the state of the art by taking knowledge entity as 
the research unit to move bibliometrics to discovery knowledge. It refines Swanson's method by utilizing 
B terms as knowledge entities. This paper uses Metformin as an example to form an entity-entity citation 
network based on literatures related to Metformin and calculates the network features of this network. It 
compares the centrality ranks of the network with results from the CTD. Entitymetric results, identifying 
the interaction of Metformin with diseases, drugs, and genes, were consistent with the CTD thereby 
demonstrating the usefulness of the entity level bibliometric approach to detect most of the outstanding 
interactions manually curated in the CTD.  
 
The results also show that our approach is complimentary to CTD. The CTD reported that 124 genes 
interact with metformin. Out of the genes identified by our meso-level analysis, we identified 30 unique 
gene interactions with metformin, and among these 30 genes, eight matched with the CTD. We conducted 
a literature review to find whether the 22 unmatched genes interact with metformin. Table 8 shows the list 
of the genes found to be in interaction with metformin. 
 
Because of manual curation, the CTD can provide only a limited coverage of interactions among bio-
entities. Therefore, interactions identified by our approach, but which are not found in the CTD, are not 
necessarily insignificant, but rather may indicate a novel interaction not previously reported and worthy 
of further investigation.  For example, a recent study by Elia et al. [80] shows that Metformin changes the 
peroxisome proliferator-activated receptor in the uterine tissue of mice. This interaction between 
Metformin and peroxisome proliferator-activated receptor is not reported in the CTD, but our approach 
identified an interaction between these two entities. Another example is our identification of an 
interaction between metformin and resistin which is supported by the recent discovery of Labuzek et al. 
[70] that Metformin treatment had a positive impact on up-regulating resistin.  Explained by these 
examples, we expect our approach could infer other potential interactions which could later be confirmed 
by clinical experiments.  
 
Literature-based knowledge discovery aims to connect the disconnected scientific entities to generate new 
knowledge. Although data-based knowledge discovery is based on more stringently validated data from 
experiments or clinical trials, the benefit of literature-based discovery can also be enormous. The 
connections between concepts in scientific literature can co-occur if two concepts are co-occur in a 
predefined context (e.g., title, abstract, one sentence, or one paragraph), can cite if the paper mentioning 
concept A cites the paper discovering/discussing concept B, and can co-cite if the paper mentioning 
concept A and the paper containing concept B are co-cited by other articles.  
 
Divided specialization fragments science and disconnects adjacent disciplines. Scientific collaboration 
glues science back together and connects these disconnections. Scientific articles are co-authored based 
on needed expertise and interlinked through citations. Today, data exists in diverse formats (e.g., textual, 
visual, and numeric) and are available in technical reports, clinical trials, gene or protein sequence 
databases, patient records, medical device recordings, and sensor recordings. Dotted knowledge can be 
connected by mining data across boundaries. For example, co-author connections in articles can reflect 
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scientific collaboration patterns and gene co-occurrence connections in articles can identify potential 
association between genes. The overlay of co-author networks with gene co-occurrence networks can 
portray the entity-oriented scientific collaboration landscapes.  
 
The problem solving style in the biomedical domain is diagnostic. Generating and testing hypotheses are 
traditions in scientific discovery in the biomedical domain. Given the fast growth in scientific literature, 
literature-based approaches for generating hypotheses are quickly emerging. Blagosklonny and Pardee 
[75] proposed that conceptual biology should take advantage of millions of accumulated data in databases 
and a variety of sources from thousands of journal articles to generate new knowledge "by reviewing 
these accumulated results in a concept-driven manner, linking them into testable chains and networks" 
(p.373). Mining and connecting biological entities in published articles can integrate unknown knowledge 
and should work closely with lab experimental verification. As Swanson [39] argued “neither relationship 
by itself is necessarily of much interest, but two literatures that are both non-interactive and yet logically 
related may have the extraordinary property of harboring undiscovered causal connections” (p. 131). As 
mentioned in the Related Work section, it is hard to apply Swanson's method without knowing the A and 
C terms. The recent test conducted by us shows some promising results that co-word analysis can be used 
to identify potential A or C terms. Citation analysis can unveil the disconnected knowledge and co-
citation can discover implicit knowledge connections. The combination of both could help us to develop a 
synthetic mechanism to enable knowledge discovery, which could strike up new developments and 
applications. 
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Figure 6. In-degree and out-degree distribution of the Metformin entity-entity citation network 
 
 
 
Tables 
Table 1. Metformin naming variations and related Genes and Diseases 
Brand Name Fortamet, Apo-Metformin, Gen-Metformin, Glucophage, Glucophage XR, 
Glumetza, Glycon, Mylan-Metformin, Novo-Metformin, Nu-Metformin, 
PMS-Metformin, Ran-Metformin, Ratio-Metformin, Riomet, Sandoz 
Metformin, Teva-Metformin 
Synoym LA-6023 
ACT Code A10BA02 
IUPAC name 1-carbamimidamido-N,N-dimethylmethanimidamide 
Target (Three Synonyms) 5'-AMP-activated protein kinase subunit beta-1, AMPK beta-1 chain, 
AMPKb 
CasRN 657-24-9 
Related Diseases Alstrom Syndrome, Amyloidosis, Atrophy, Diabetes Complications, 
Diabetes Mellitus, Diabetes Mellitus (Experimental), Diabetes 
Mellitus(Type 2), Diabetic Angiopathies, Diabetic Nephropathies, 
Hyperandrogenism, Hyperglycemia, Hyperinsulinism, Hypertension, 
Insulin Resistance, Myocardial Infarction, Obesity, Polycystic Ovary 
Syndrome, Albuminuria 
Related Genes CASP3, CASP7, CASP8, FASN, HRH2, MMP2, MMP9, NR1I3, PLAT, 
PRKAA1, PRKAA2, SLC15A1 
 
Table 2. Top 20 ranked bio-entities with high frequency in the citing article set 
Frequency Entity Entity ID Entity Name 
1458 DISEASE D009765 Obesity 
1213 DISEASE D006973 Hypertension 
989 DISEASE D004194 Disease 
670 DISEASE D003920 diabetes mellitus 
622 DISEASE D007333 insulin resistance 
555 DISEASE D009203 myocardial infarction 
552 GENE P01308 Insulin 
362 DISEASE D001284 Atrophy 
351 DISEASE D013577 Syndrome 
275 DISEASE D006943 Hyperglycemia 
257 DISEASE D007249 Inflammation 
249 GENE Q9UH22 Large 
205 GENE Q9P2X3 Impact 
193 DISEASE D050177 Overweight 
189 DISEASE D003643 Death 
162 DISEASE DB04540 Cholesterol 
141 DISEASE D050197 Atherosclerosis 
137 DISEASE D001835 body weight 
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137 DISEASE D020521 Stroke 
 
Table 3. Top 20 highly cited bio-entities 
Num. of 
Papers 
Entity Entity ID Entity Name 
22867 DRUG DB04077 Glycerol 
22846 DRUG DB04557 arachidonic acid 
22511 DISEASE D004890 Erythema 
19978 DISEASE D004194 Disease 
13323 GENE P01308 Insulin 
11332 DISEASE D009765 Obesity 
10422 DISEASE D006973 Hypertension 
6583 DISEASE D007333 insulin resistance 
5769 DISEASE D003920 diabetes mellitus 
5630 DISEASE D013577 Syndrome 
5604 GENE Q9UH22 Large 
4721 DISEASE D003643 Death 
4347 DISEASE D007249 Inflammation 
4289 DRUG DB04540 Cholesterol 
4023 DISEASE D009203 myocardial infarction 
3294 DISEASE D001835 body weight 
3278 DISEASE D050197 Atherosclerosis 
3211 GENE Q9P2X3 Impact 
2864 DRUG DB00435 nitric oxide 
2427 DRUG DB01373 Calcium 
 
Table 4. In-degree centrality (top 20) 
Rank Disease Drug Gene All Entities 
1 DISEASE_disease DRUG_glycerol GENE_large DISEASE_disease 
2 DISEASE_erythema DRUG_arachidonic acid GENE_insulin DRUG_glycerol 
3 DISEASE_syndrome DRUG_calcium GENE_impact DISEASE_erythema 
4 DISEASE_death DRUG_cholesterol GENE_set DRUG_arachidonic acid 
5 DISEASE_hypertension DRUG_nitric oxide GENE_tnf GENE_large 
6 DISEASE_obesity DRUG_potassium GENE_lep DISEASE_syndrome 
7 DISEASE_inflammation DRUG_glutathione GENE_hr DISEASE_death 
8 DISEASE_diabetes mellitus DRUG_ester GENE_ca2 GENE_insulin 
9 
DISEASE_necrosis 
 
DRUG_dexamethasone GENE_camp GENE_impact 
10 DISEASE_insulin resistance DRUG_norepinephrine GENE_met DISEASE_hypertension 
11 DISEASE_body weight DRUG_zinc GENE_rest DISEASE_obesity 
12 DISEASE_atherosclerosis DRUG_heparin GENE_albumin DISEASE_inflammation 
13 DISEASE_infection DRUG_acetylcholine GENE_renin DISEASE_diabetes mellitus 
14 DISEASE_stroke DRUG_Dopamine GENE_insulin receptor GENE_set 
15 DISEASE_hypertrophy DRUG_iron GENE_glucagon DISEASE_necrosis 
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16 
DISEASE_myocardial 
infarction DRUG_aldosterone GENE_plasminogen DISEASE_insulin resistance 
17 DISEASE_heart failure DRUG_adenosine GENE_jun DRUG_calcium 
18 DISEASE_hyperglycemia DRUG_l-arginine GENE_myoglobin DISEASE_body weight 
19 DISEASE_ischemia DRUG_epinephrine GENE_cat DISEASE_atherosclerosis 
20 
DISEASE_coronary artery 
disease 
DRUG_creatine GENE_tg DRUG_cholesterol 
 
Table 5. Out-degree centrality (top 20) 
Rank Disease Drug Gene All Entities 
1 DISEASE_disease DRUG_cholesterol GENE_insulin DISEASE_disease 
2 DISEASE_obesity DRUG_calcium GENE_large DISEASE_obesity 
3 DISEASE_hypertension DRUG_nitric oxide GENE_impact DISEASE_hypertension 
4 DISEASE_diabetes mellitus DRUG_aldosterone GENE_lep DISEASE_diabetes mellitus 
5 DISEASE_insulin resistance DRUG_glycerol GENE_tnf DISEASE_insulin resistance 
6 DISEASE_atrophy 
DRUG_arachidonic 
acid GENE_renin GENE_insulin 
7 DISEASE_syndrome DRUG_metformin GENE_insulin receptor DISEASE_atrophy 
8 DISEASE_inflammation DRUG_potassium GENE_set DISEASE_syndrome 
9 
DISEASE_myocardial 
infarction 
DRUG_zinc GENE_mmp9 DISEASE_inflammation 
10 DISEASE_hyperglycemia DRUG_fructose GENE_mmp2 GENE_large 
11 DISEASE_death DRUG_norepinephrine GENE_resistin 
DISEASE_myocardial 
infarction 
12 DISEASE_atherosclerosis DRUG_rosiglitazone GENE_glucagon DISEASE_hyperglycemia 
13 DISEASE_stroke DRUG_glutathione GENE_ace DISEASE_death 
14 DISEASE_infection DRUG_Dopamine GENE_pah GENE_impact 
15 DISEASE_body weight DRUG_pioglitazone 
GENE_peroxisome 
proliferator-activated 
receptor gamma 
DISEASE_atherosclerosis 
16 DISEASE_heart failure DRUG_sildenafil GENE_cd4 DISEASE_stroke 
17 DISEASE_fibrosis DRUG_ethanol GENE_crp DRUG_cholesterol 
18 DISEASE_hypertrophy DRUG_iron GENE_albumin DISEASE_infection 
19 
DISEASE_cardiovascular 
diseases DRUG_urea GENE_hr DISEASE_body weight 
20 DISEASE_necrosis DRUG_sucrose GENE_rhodopsin DISEASE_heart failure 
 
Table 6. Closeness centrality (top 20) 
Rank Disease Drug Gene All Entities 
1  DISEASE_disease DRUG_glycerol GENE_insulin DISEASE_disease 
2 DISEASE_obesity DRUG_arachidonic acid GENE_large DISEASE_obesity 
3 DISEASE_hypertension DRUG_cholesterol GENE_impact DISEASE_hypertension 
4 DISEASE_diabetes mellitus DRUG_calcium GENE_set GENE_insulin 
5 DISEASE_syndrome DRUG_nitric oxide GENE_tnf DISEASE_diabetes mellitus 
6 DISEASE_insulin resistance DRUG_aldosterone GENE_lep DISEASE_syndrome 
7 DISEASE_atrophy DRUG_potassium GENE_renin DISEASE_insulin resistance 
8 DISEASE_inflammation DRUG_zinc GENE_insulin receptor GENE_large 
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9 DISEASE_death DRUG_glutathione GENE_hr DISEASE_atrophy 
10 
DISEASE_myocardial 
infarction DRUG_norepinephrine GENE_camp DISEASE_inflammation 
11 DISEASE_hyperglycemia DRUG_Dopamine GENE_glucagon DISEASE_death 
12 DISEASE_erythema DRUG_iron GENE_myoglobin 
DISEASE_myocardial 
infarction 
13 DISEASE_atherosclerosis DRUG_rosiglitazone GENE_albumin GENE_impact 
14 DISEASE_infection DRUG_ester GENE_plasminogen DISEASE_hyperglycemia 
15 DISEASE_stroke DRUG_fructose GENE_cd4 DRUG_glycerol 
16 DISEASE_body weight DRUG_metformin GENE_jun DRUG_arachidonic acid 
17 DISEASE_necrosis DRUG_dexamethasone 
GENE_peroxisome 
proliferator-activated 
receptor gamma 
DISEASE_erythema 
18 DISEASE_heart failure DRUG_l-arginine GENE_rest DISEASE_atherosclerosis 
19 DISEASE_hypertrophy DRUG_urea GENE_ace DISEASE_infection 
20 DISEASE_fibrosis DRUG_adenosine GENE_resistin DISEASE_stroke 
 
Table 7. Betweenness centrality (top 20) 
Rank Disease Drug Gene All Entities 
1 DISEASE_disease DRUG_glycerol GENE_large DISEASE_disease 
2 DISEASE_obesity DRUG_arachidonic acid GENE_insulin DISEASE_obesity 
3 DISEASE_hypertension DRUG_calcium GENE_impact DISEASE_hypertension 
4 DISEASE_syndrome DRUG_cholesterol GENE_set GENE_large 
5 DISEASE_diabetes mellitus DRUG_nitric oxide GENE_tnf DISEASE_syndrome 
6 DISEASE_atrophy DRUG_zinc GENE_lep GENE_insulin 
7 DISEASE_insulin resistance DRUG_potassium GENE_insulin receptor DISEASE_diabetes mellitus 
8 DISEASE_death DRUG_Dopamine GENE_renin DISEASE_atrophy 
9 DISEASE_inflammation DRUG_aldosterone GENE_myoglobin DISEASE_insulin resistance 
10 
DISEASE_myocardial 
infarction DRUG_iron GENE_mmp9 DISEASE_death 
11 DISEASE_hyperglycemia DRUG_norepinephrine GENE_camp DISEASE_inflammation 
12 DISEASE_infection DRUG_glutathione GENE_rest 
DISEASE_myocardial 
infarction 
13 DISEASE_erythema DRUG_sucrose GENE_cd4 GENE_impact 
14 DISEASE_body weight DRUG_rosiglitazone GENE_hr DISEASE_hyperglycemia 
15 DISEASE_stroke DRUG_guanine GENE_plasminogen DISEASE_infection 
16 DISEASE_atherosclerosis DRUG_dexamethasone GENE_albumin DRUG_glycerol 
17 DISEASE_necrosis DRUG_testosterone GENE_ar DRUG_arachidonic acid 
18 DISEASE_heart failure DRUG_adenosine GENE_glucagon DISEASE_erythema 
19 DISEASE_fibrosis DRUG_ester GENE_rhodopsin DISEASE_body weight 
20 DISEASE_hypertrophy DRUG_epinephrine GENE_mmp2 DISEASE_stroke 
 
Table 8. A list of genes found to be in interaction with metformin by literature  
Interaction Found Interacting Gene with Metformin 
X Large 
O Insulin 
X Impact 
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X Set 
X Hr 
O ca2 
O Camp 
X Met 
X Rest 
O Albumin 
X Renin 
O insulin receptor 
O Plasminogen 
O Myoglobin 
X Tg 
O Resistin 
O Ace 
X Pah 
O peroxisome proliferator-activated receptor 
gamma 
O cd4 
X Rhodopsin 
X Ar 
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Figure 1. Entitymetrics. 
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Figure 2. A fraction of bio-entity dictionary. 
 
 
 
 
Figure 3. From paper citation to entity citation. 
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Figure 4. An overview of Entity Citation Network generation. 
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Figure 5. The longest path of the network. 
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Figure 6. In-degree and out-degree distribution of the Metformin entity-entity citation network. 
